BackBriaCell Therapeutics Overview

BriaCell Therapeutics EBIT

Latest ebit for BCTXL: $-31M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$12.39M
↓ 55.65% YoY

As of Jul 31, 2026

Annual EBIT (TTM)

-$30.53M
↓ 15.37% YoY

Trailing 12 months ending Jul 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

BriaCell Therapeutics (BCTXL) FAQ

The latest EBIT for BCTXL is $-31M as of July 2026. That compares with $-26M in the prior-year period — down 15.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside BriaCell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BCTXL's EBIT moved from $-26M to $-31M — a 15.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BriaCell Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, BCTXL currently prints $-31M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at BriaCell Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-31M for BCTXL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting BCTXL's EBIT ($-31M), review year-over-year change from $-26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers